How should a reproductive‑age woman with heavy menstrual bleeding and low hemoglobin and hematocrit be evaluated and managed?

Management of Heavy Menstrual Bleeding with Low Hemoglobin and Hematocrit

Start combined hormonal contraceptives or levonorgestrel-releasing intrauterine system (LNG-IUS) immediately while simultaneously initiating oral iron supplementation (60-120 mg elemental iron daily) and conducting a focused diagnostic workup to identify the underlying cause.

Immediate Diagnostic Workup

Obtain the following tests at presentation:

• Hemoglobin and hematocrit (already documented as low)
• Ferritin level - essential for confirming iron deficiency (threshold <30-45 µg/L indicates deficiency) 1, 2
• Pregnancy test (β-hCG) - mandatory first step 1
• Thyroid-stimulating hormone (TSH) and prolactin - to rule out ovulatory dysfunction 1
• Coagulation screening if patient reports flooding (changing pad/tampon more than hourly), clots ≥1 inch diameter, or personal/family bleeding history - these strongly suggest an underlying bleeding disorder requiring hematology referral 3

Pelvic imaging with transvaginal ultrasound to identify structural causes (polyps, adenomyosis, leiomyomas, malignancy) using the PALM-COEIN classification system 1, 4. If the endometrium cannot be completely visualized due to fibroids or adenomyosis, proceed to MRI with diffusion-weighted imaging 4.

Endometrial biopsy is indicated if the patient is >45 years old, has risk factors for endometrial cancer, or has failed medical management 1.

Immediate Medical Management

Hormonal Therapy (First-Line)

Choose based on contraceptive needs and contraindications:

LNG-IUS (Mirena) - Most effective option with 93% reduction in menstrual blood loss at 6 months and highest patient compliance 5. This is the preferred first-line treatment for heavy menstrual bleeding 1, 5.

Combined hormonal contraceptives (CHCs) - Effective alternative if LNG-IUS is declined or contraindicated 1, 5.

Alternatives if above are contraindicated:

• Progestin-only pills
• Injectable depot medroxyprogesterone acetate (DMPA) - showed 78% reduction in bleeding at 3 months 5
• Oral norethisterone 5

Hemostatic Therapy (Adjunctive)

Tranexamic acid - Can be used alone or combined with hormonal therapy for additional bleeding reduction 6, 7. Administer 5-7 days during menses 6.

Iron Replacement Strategy

Oral Iron (First-Line for Most Patients)

Prescribe 60-120 mg elemental iron daily 8, 2:

• Ferrous sulfate, ferrous fumarate, or ferrous gluconate are reasonable first choices (least expensive) 2
• Take on empty stomach when possible, or with meals if not tolerated 2
• Adding 500 mg vitamin C enhances absorption 2
• Continue for 2-3 months after hemoglobin normalizes to replenish iron stores 8

Reassess hemoglobin at 4 weeks - expect ≥1 g/dL increase if compliant and no ongoing blood loss 8. If no response despite compliance, consider:

• Intravenous iron therapy
• Further evaluation for malabsorption or continued blood loss
• Thalassemia trait or sickle cell trait in women of African, Mediterranean, or Southeast Asian ancestry 8

Intravenous Iron (Specific Indications)

Use IV iron when 2, 9:

• Hemoglobin <9 g/dL (severe anemia)
• Oral iron intolerance or non-response after 4 weeks
• Malabsorption conditions (celiac disease, inflammatory bowel disease)
• Need for rapid iron repletion before surgery
• Patient preference after discussion of risks/benefits

Blood Transfusion (Rare, Severe Cases Only)

Reserve for hemodynamically unstable patients or those with severe symptomatic anemia requiring immediate correction 8, 10. Note that transfusion does not independently improve long-term hematologic recovery compared to iron therapy alone 10.

Follow-Up Protocol

At 4 weeks:

• Repeat hemoglobin - expect ≥1 g/dL increase 8
• Assess bleeding pattern improvement
• Evaluate medication tolerance and adherence

At 3-6 months:

• Repeat hemoglobin and ferritin 8, 11
• Critical caveat: Ferritin recovery lags behind hemoglobin normalization 10, 12. Continue iron supplementation for 2-3 months after hemoglobin normalizes to restore iron stores 8
• Assess treatment satisfaction

When Medical Management Fails

If bleeding persists despite 3-6 months of appropriate medical therapy or patient finds it unacceptable 1:

Further investigation required:

• Hysteroscopy for direct visualization of endometrial cavity 1
• Saline infusion sonohysterography (96-100% sensitivity for intracavitary lesions) 1

Surgical options (in order of invasiveness):

1. Hysteroscopic myomectomy - for submucosal fibroids 13
2. Endometrial ablation - for patients with no desire for future fertility; contraindicated if pregnancy desired 13
3. Uterine artery embolization - comparable to myomectomy for symptom relief with lower complication rates 13
4. Hysterectomy - definitive treatment when other options fail, contraindicated, or not tolerated 1, 13

Critical Pitfalls to Avoid

• Do not delay iron replacement while waiting for diagnostic workup completion - anemia treatment should begin immediately 8, 2
• Do not stop iron supplementation when hemoglobin normalizes - continue 2-3 months longer to replenish stores 8
• Do not miss bleeding disorders - flooding, large clots, or bleeding history mandate hematology referral before attributing everything to gynecologic causes 3
• Do not perform endometrial ablation in women desiring future fertility - high risk of pregnancy complications 13
• Do not use transfusion routinely - it does not improve long-term outcomes compared to iron therapy 10